Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if injecting a local anesthetic, or numbing medication, above each hip will decrease the amount of narcotic pain medicine that is typically required by a patient after a cesarean delivery. Ultrasound pictures will be used to guide placement of this injection. Either ropivicaine (a type of numbing medication called a local anesthetic) or a placebo (saline) will be injected. For 24 hours, you will be given a button to press when you have pain. When the button is pressed, you will be given a small amount of pain medication called hydromorphone through your IV. You will also be given a pain medication called ketorolac through your IV every 8 hours for 24 hours after surgery.
| Condition | Intervention |
|---|---|
|
Cesarean Section |
Drug: 0.5% ropivacaine Drug: 0.9% sodium chloride |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane Block After Cesarean Delivery in Patients With a BMI > 30 |
- hydromorphone consumed by patient controlled analgesia in the first 24 hours after cesarean delivery [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
- Categorical pain scores and Visual Analog Scale (VAS) pain scores (at rest and with movement), nausea and sedation will be assessed to evaluate narcotic side effects [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | October 2010 |
| Estimated Study Completion Date: | October 2011 |
| Estimated Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 20 ml per side of 0.5% ropivacaine
Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
|
Drug: 0.5% ropivacaine
20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
|
|
Placebo Comparator: 20 ml per side of 0.9% sodium chloride
Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
|
Drug: 0.9% sodium chloride
20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18 years or over
- ASA class 1 , 2 or 3
- BMI greater than 30 kg/m2 (as recorded at the patient's last clinic appointment or as measured on the day of delivery)
- Scheduled for cesarean section via Pfannenstiel incision (with or without a tubal ligation)
- 150 cm or taller
- Informed consent obtained
Exclusion Criteria:
- ASA class 4
- Age under 18
- Relevant drug allergy
- Contraindication to spinal anesthesia
- Height < 150 cm
- Patient receiving medical therapies considered to result in a tolerance to opioids
- Any other major surgical procedure performed other than cesarean delivery with or without tubal ligation
- Patient with relevant contraindications to ketorolac, such as history of gastrointestinal bleeding or impaired renal function
- Patient refusal
Contacts and Locations| United States, Louisiana | |
| Ochsner Clinic Foundation | |
| New Orleans, Louisiana, United States, 70121 | |
| Principal Investigator: | Stuart Hart, MD | Ochsner Clinic Foundation |
More Information
Additional Information:
Publications:
| Responsible Party: | Stuart Hart, Director of Obstetric Anesthesiology, Ochsner Health System |
| ClinicalTrials.gov Identifier: | NCT01217580 History of Changes |
| Other Study ID Numbers: | 2010.091.C, PI-Hart |
| Study First Received: | October 7, 2010 |
| Last Updated: | October 25, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Ochsner Health System:
|
c-section cesarean section TAP block pain pain after delivery |
pain after C-section pain after C-section delivery pain after cesarean delivery pain after cesarean |
Additional relevant MeSH terms:
|
Ropivacaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |
Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013